BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
Portfolio Pulse from
BioCryst Pharmaceuticals reported a 34% year-over-year increase in ORLADEYO net revenue for 2024, reaching $437 million. The company projects ORLADEYO revenue to rise to $515-$535 million in 2025, with total revenue, including RAPIVAB, expected to be $540-$560 million. BioCryst achieved operating profit in 2024 and anticipates approaching EPS profitability and positive cash flow in the second half of 2025. A new drug application for ORLADEYO granules for children is planned for 2025, and the pipeline is advancing with treatments for Netherton syndrome and diabetic macular edema.
January 10, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioCryst Pharmaceuticals reported a significant increase in ORLADEYO revenue for 2024 and projects further growth in 2025. The company achieved operating profit and expects to approach EPS profitability and positive cash flow in the latter half of 2025. New drug applications and pipeline advancements are planned.
The 34% increase in ORLADEYO revenue and the projection of further growth in 2025 are positive indicators for BioCryst's financial health. Achieving operating profit and aiming for EPS profitability and positive cash flow in 2025 are strong signals of the company's improving financial performance. The planned new drug applications and pipeline advancements further enhance the company's growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100